Literature DB >> 2454732

Mucin-like antigens in a human pancreatic cancer cell line identified by murine monoclonal antibodies SPan-1 and YPan-1.

J J Ho1, Y S Chung, Y Fujimoto, N Bi, W Ryan, S Z Yuan, J C Byrd, Y S Kim.   

Abstract

The antigenic determinant recognized by monoclonal antibody SPan-1 is greatly elevated in sera of patients with pancreatic cancer but not in sera of normal individuals. Here we describe the mucin-like characteristics of the SPan-1 antigen isolated from culture medium and xenografts of the human pancreatic cancer cell line SW-1990. YPan-1, another pancreatic cancer associated monoclonal antibody, also reacts with the SPan-1 antigen. The SPan-1/YPan-1 antigens have densities of 1.4-1.5 g/ml and elute in the void volume of Sepharose CL-2B columns. They are resistant to degradation by chondroitinase ABC, nitrous acid, and hyaluronidase but susceptible to protease digestion and reductive beta-elimination. All these characteristics suggest that the SPan-1 and YPan-1 determinants are carried on mucinous antigens. Both SPan-1 and YPan-1 immunoreactivities are unaffected by boiling or by alkylation and reduction of the mucins while they are abolished by mild periodate oxidation or neuraminidase and are markedly decreased by wheat germ agglutinin. Thus, their antigenic determinants are composed principally of carbohydrates with sialic acid, an absolute requirement for reactivity. However, the epitope specificities of SPan-1 and YPan-1 are different since YPan-1 does not compete with SPan-1 for binding to antigen. Moreover, YPan-1 and SPan-1 can be distinguished from several other sialic acid requiring, cancer associated antibodies such as B72.3, CSLEX-1, DU-PAN-2, OC-125, and 19-9 by either their epitope characteristics or their tissue reactivity patterns.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2454732

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  11 in total

1.  Differential mucin gene expression in human pancreatic and colon cancer cells.

Authors:  S Yonezawa; J C Byrd; R Dahiya; J J Ho; J R Gum; B Griffiths; D M Swallow; Y S Kim
Journal:  Biochem J       Date:  1991-06-15       Impact factor: 3.857

Review 2.  Mucin glycoproteins in neoplasia.

Authors:  Y S Kim; J Gum; I Brockhausen
Journal:  Glycoconj J       Date:  1996-10       Impact factor: 2.916

Review 3.  Composition and production of pancreatic tumor related antigens.

Authors:  H E Appert
Journal:  Int J Pancreatol       Date:  1990 Aug-Nov

4.  SPan-1 is a useful prognostic marker for patients with stage IV gastric cancer who underwent palliative gastrectomy: a retrospective multivariate study.

Authors:  Naoshi Kubo; Masaichi Ohira; Katsunobu Sakurai; Takahiro Toyokawa; Hiroaki Tanaka; Kazuya Muguruma; Hisashi Nagahara; Kenjiro Kimura; Eiji Noda; Ryosuke Amano; Nobuya Yamada; Masakazu Yashiro; Kiyoshi Maeda; Tetsuji Sawada; Kosei Hirakawa
Journal:  World J Surg       Date:  2013-07       Impact factor: 3.352

5.  Role of SPan-1 antigen in adhesion of human colon cancer cells to vascular endothelium.

Authors:  N Yamada; Y S Chung; T Sawada; M Okuno; M Sowa
Journal:  Dig Dis Sci       Date:  1995-05       Impact factor: 3.199

6.  Polymorphic epithelial mucin from the sera of advanced breast cancer patients--isolation and partial characterisation.

Authors:  C O'Sullivan; M R Price; R W Baldwin
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

7.  Wheatgerm agglutinin-mediated toxicity in pancreatic cancer cells.

Authors:  R E Schwarz; D C Wojciechowicz; A I Picon; M A Schwarz; P B Paty
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

8.  Radioimmunodetection with 111In-labeled monoclonal antibody Nd2 in patients with pancreatic cancer.

Authors:  Y S Chung; T Sawada; Y Kondo; K Hirayama; A Inui; Y Yamashita; B Nakata; T Okamura; H Ochi; J J Ho; Y S Kim; M Sowa
Journal:  Jpn J Cancer Res       Date:  1997-04

9.  Similarity and co-expression of tumour-associated antigens recognised by different monoclonal antibodies.

Authors:  H Sakahara; T Saga; K Endo; T Kousaka; M Hosono; H Kobayashi; M Shirato; J Konishi
Journal:  Br J Cancer       Date:  1993-11       Impact factor: 7.640

10.  Establishment of a new human extrahepatic bile duct carcinoma cell line (OCUCh-LM1) and experimental liver metastatic model.

Authors:  N Yamada; Y S Chung; Y Arimoto; T Sawada; S Seki; M Sowa
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.